US20020068072A1 - Use of a substance p antagonist in a pharmaceutical composition - Google Patents

Use of a substance p antagonist in a pharmaceutical composition Download PDF

Info

Publication number
US20020068072A1
US20020068072A1 US08/921,524 US92152497A US2002068072A1 US 20020068072 A1 US20020068072 A1 US 20020068072A1 US 92152497 A US92152497 A US 92152497A US 2002068072 A1 US2002068072 A1 US 2002068072A1
Authority
US
United States
Prior art keywords
derivatives
use according
substance
composition
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US08/921,524
Inventor
Olivier De Lacharriere
Lionel Breton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9469929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020068072(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US08/921,524 priority Critical patent/US20020068072A1/en
Publication of US20020068072A1 publication Critical patent/US20020068072A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • the present invention relates to the use of a substance P antagonist for the preparation of a pharmaceutical composition for treating certain skin disorders of neurogenic origin.
  • this composition permits the treatment, topically, orally or by injection, of lichens, in particular lichen planus and pigmentary lichens; prurigo, and especially actinic prurigo, Besnier's or Hebra's prurigo or strophulus or Hyde's disease; pruriginous toxicoderma and severe pruritus of neurogenic origin, especially those of patients who have undergone haemodialysis and AIDS patients, and cholestatic or biliary pruritus. Pruriginous toxicoderma is, in particular, the outcome of the intake of a medicinal product; these disorders are very different from urticaria, and do not involve any contact reaction.
  • lichen planes and pigmentary lichens were treated by means of local corticoids or of PUVA therapy.
  • Corticoids are admittedly very effective for calming the symptoms, but unfortunately they display side-effects which are often very detrimental, such as atrophy or infections, especially fungal or bacterial infections.
  • PUVA therapy is the local irradiation of the diseased skin with UVA after absorption of a photosensitizing substance (psoralen) This technique has the serious drawbacks of a light-induced ageing which can, more often than not, give rise to skin cancers.
  • this treatment is not ambulatory, commonly obliging the patients to go to a specialized centre for the entire treatment period, which is very restrictive and limits the exercising of their occupation.
  • Prurigo is also treated with local corticoids, PUVA therapy or thalidomide.
  • Local corticoids and PUVA therapy have the above drawbacks.
  • Thalidomide has the major drawback of being teratogenic, thereby prohibiting its use in pregnant women.
  • the closely regulated prescription of this drug limits its use.
  • Pruriginous toxicoderma is currently treated by means of local corticoids and/or antihistamines: its treatment hence has the same drawbacks as those mentioned above.
  • the subject of the present invention is, in fact, the use in a pharmaceutically or dermatologically acceptable medium of one or more substance P antagonists enabling certain skin disorders to be treated effectively while remedying the. disorders mentioned above.
  • Substance P is a polypeptide chemical component produced and released by a nerve ending. It belongs to the tachykinin family. Substance P participates, in particular, in the transmission of pain and in central nervous system disorders such as anxiety and schizophrenia, in respiratory and inflammatory disorders, in gastrointestinal disorders, in rheumatic disorders and in certain skin disorders such as eczema, psoriasis, urticaria and contact dermatitis.
  • the invention relates to the symptomatic treatment (itching, irritation) of a dermatosis and not to the treatment of the disorder in itself.
  • the invention relates to the use of a substance P-antagonist for treating the discomfort associated with certain dermatoses, and especially with eczema and with atopic dermatitis, and not to the treatment of the other signs of these dermatoses (vesicles, erythema, and the like).
  • allergy is an immunological process which takes place only when an allergen is present and which affects only certain sensitized subjects, whereas disorders of neurogenic origin may affect any individual.
  • the subject of the present invention is the use of at least one substance P antagonist for the preparation of a pharmaceutical or dermatological composition for treating lichens, prurigo, pruriginous toxicoderma and severe pruritus of neurogenic origin.
  • the composition of the invention contains a pharmaceutically or dermatologically acceptable medium, that is to say a medium compatible with the tissues, mucosae, skin, nails and hair.
  • a pharmaceutically or dermatologically acceptable medium that is to say a medium compatible with the tissues, mucosae, skin, nails and hair.
  • the composition containing one or more substance P antagonists may be injected, swallowed or applied to the skin, in particular of the face, neck, hair, nails, major folds or any other area of the skin of the body, and the mucosae (buccal, jugal, gingival, genital, anal).
  • [0017] have a pharmacological activity antagonistic to substance P, that is to say induce a coherent pharmacological response in at least one of the following two tests:
  • the antagonist substance must decrease the extravasation of plasma through the vascular wall induced by capsaicin or by an antidromic nervous stimulation, or alternatively
  • the antagonist substance must cause an inhibition of the smooth muscle contraction induced by the administration of substance P.
  • the substance P antagonist can, in addition, have a selective affinity for the tachykinin NK1 receptors.
  • the substance P antagonist of the invention may be functional or receptor-directed, that is to say may inhibit the synthesis and/or release of substance P, or prevent its binding and/or modulate its action.
  • the substance P antagonist of the invention can be, in particular, a peptide or a non-peptide derivative, and more specifically a compound containing a nitrogen, sulphur or oxygen heterocycle, or a compound comprising a nitrogen atom linked directly or indirectly to a benzene ring.
  • Tyr represents tyrosine
  • D-Phe represents D-phenylalanine
  • D-His represents D-histidine
  • Leu represents leucine
  • Met represents methionine.
  • Spantide II corresponds to the formula:
  • D-NicLys represents D-lysine nicotinate
  • Pro represents proline
  • 3-Pal represents 3-pyridylalanine
  • D-Cl 2 Phe represents D-dichlorophenylalanine
  • D-Trp represents D-tryptophan
  • Leu represents leucine
  • Nle represents norleucine
  • the non-peptide substance P antagonists which can be used in the invention are, in particular, compounds comprising a hetero atom linked directly or indirectly to a benzene ring or contained in a heterocycle.
  • this hetero atom is an oxygen, nitrogen or sulphur atom.
  • heterocyclic compound containing a nitrogen atom those described in the following documents may be used in the invention: EP-A-360,390, EP-A-429,366, EP-A-430,771, EP-A-499,313, EP-A-514,273, EP-A-514,274, EP-A-514,275, EP-A-514,276, EP-A-520,555, EP-A-528,495, EP-A-532,456, EP-A-545,478, EP-A-558,156, WO-A-90/05525, WO-A-90/05729, WO-A-91/18878, WO-A-91/18899, WO-A-92/12151, WO-A-92/15585, WO-A-92/17449, WO-A-92/20676, WO-A-93/00330, WO-A-93/00331, WO-A-93/01159, WO-A-93/01
  • the compound comprising at least one nitrogen heterocycle is a 2-tricyclyl-2-aminoethane derivative, a spirolactam derivative, a quinuclidine derivative, an azacyclic derivative, an aminopyrrolidine derivative, a piperidine derivative, an aminoazaheterocycle or an isoindole derivative.
  • the compounds containing a sulphur or oxygen atom which can be used in the invention are, in particular, heterocyclic oxygen or sulphur compounds such as furan derivatives, benzofuran derivatives, thiophene derivatives and benzothiophene derivatives, optionally containing nitrogenous substituents, such as the heterocyclic compounds described in the documents U.S. Pat. No. 4,931,459, U.S. Pat. No. 4,910,317 and EP-A-299,457, and more especially alkoxy- and/or aryloxytetrazolylbenzofurancarboxamides or alkoxy-and/or aryloxytetrazolylbenzothiophenecarboxamides,
  • the substance P antagonists may be synthesized or extracted from natural products (plant or animal).
  • the substance P antagonist can preferably be used in an amount ranging from 0.000001 to 5% by weight relative to the total weight of the composition, and especially in an amount ranging from 0.0001 to 0.1% by weight relative to the total weight of the composition.
  • compositions of the invention may be presented in all pharmaceutical dosage forms normally used, depending on whether the composition has to be swallowed, injected or applied to the skin or mucosae.
  • the composition may take the form, in particular, of aqueous or oily solutions or of dispersions of the lotion or serum type, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersing a fatty phase in an aqueous phase (O/W) or vice versa (W/O), or of suspensions or emulsions of soft consistency of the cream or aqueous gel type or which are anhydrous, of microemulsions or alternatively of microcapsules or microparticles, or of vesicular dispersions of the ionic and/or nonionic type.
  • These compositions are prepared according to the standard methods.
  • the composition may take the form of an aqueous or oily lotion or the form of a serum.
  • the composition may take the form of capsules, syrup, granules or tablets.
  • compositions constitute, in particular, cleansing, protective, treatment or skin care creams for the face, hands, feet, major anatomical folds or body, protective or skin care body milks, or lotions, gels or foams for care of the skin or mucosae, such as cleansing or disinfecting lotions, bath compositions and compositions containing a bactericidal agent.
  • compositions according to the invention can also consist of solid preparations constituting cleansing soaps or bars.
  • compositions may also be packaged in the form of an aerosol composition also containing a propellent agent under pressure.
  • the proportion of the fatty phase can range from 5% to 80% by weight, and preferably from 5% to 50% by weight, relative to the total weight of the composition.
  • the oils, waxes, emulsifiers and coemulsifiers used in the composition in emulsion form are chosen from those traditionally used in the cosmetics field.
  • the emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight, relative to the total weight of the composition.
  • the emulsion can, in addition, contain lipid vesicles.
  • the amount of oil can range up to more than 90% of the total weight of the composition.
  • the pharmaceutical or dermatological composition of the invention can also contain adjuvants which are customary in the fields in question, such as hydrophilic or lipophilic gelling agents, preservatives, antioxidants, solvents, perfumes, fillers, sunscreen agents, odour adsorbers and colouring matter.
  • adjuvants which are customary in the fields in question, such as hydrophilic or lipophilic gelling agents, preservatives, antioxidants, solvents, perfumes, fillers, sunscreen agents, odour adsorbers and colouring matter.
  • the amounts of these different adjuvants are those traditionally used in the cosmetics field, and are, for example, from 0.01% to 10% of the total weight of the composition.
  • These adjuvants depending on their nature, may be introduced into the fatty phase, into the aqueous phase and/or into lipid spherules.
  • oils which can be used in the invention mineral oils (liquid paraffin), vegetable oils (liquid fraction of shea butter, sunflower oil), animal oils (perhydrosqualene), synthetic oils (Purcellin oil), silicone oils or waxes (cyclomethicone) and fluorinated oils (perfluoro polyethers) may be mentioned.
  • mineral oils liquid paraffin
  • vegetable oils liquid fraction of shea butter, sunflower oil
  • animal oils perhydrosqualene
  • synthetic oils Purcellin oil
  • silicone oils or waxes cyclomethicone
  • fluorinated oils perfluoro polyethers
  • Fatty alcohols and fatty acids stearic acid
  • Waxes such as beeswax and carnauba wax or paraffin may also be used.
  • glyceryl stearate, polysorbate 60 and the PEG-6/PEG-32/glycol stearate mixture sold under the name Tefose R 63 by the company Gattefosse may be mentioned as examples.
  • solvents which can be used in the invention lower alcohols, in particular ethanol and isopropanol, and propylene glycol may be mentioned.
  • hydrophilic gelling agents carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, clays and natural gums may be mentioned, and as lipophilic gelling agents, modified clays such as bentones, metal salts of fatty acids such as aluminium stearates and hydrophobic silica may be mentioned.
  • hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, sugars and sugar derivatives, vitamins, starch, plant extracts (Aloe vera) and hydroxy acids (citric, lactic, glycolic, tartaric).
  • lipophilic active agents such as retinol (vitamin A) and its derivatives, retinoids such as 13-cis- or all-transretinoic acid, tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides, essential oils and salicylic acid and its derivatives (5-n-octanoylsalicylic).
  • compositions which follow illustrate the invention: the proportions shown are percentages by weight.
  • Composition 1 Disinfectant lotion for the face or mucosae N,N′-Bis[bis(3,5-dimethoxybenzyl)]ethylene- 5.00 diamine
  • Antioxidant 0.05 Isopropanol 40.00
  • composition 2 Face or body gel for the treatment of lichen planus N,N′-Bis[bis(3,5-dimethoxybenzyl)]ethylene- 0.05 diamine Hydroxypropylcellulose (Klucel H sold by 1.00 the company Hercules) Salicylic acid 1.00 Antioxidant 0.05 Isopropanol 40.00 Preservative 0.30 Water qs 100%
  • Composition 3 Cream (oil-in-water emulsion) for the treatment of severe pruritus N,N′-Bis[bis(3,5-dimethoxybenzyl)]ethylene- 0.2 diamine Glyceryl stearate 2.00 Lactic acid/acetic acid 1.00 Polysorbate 60 (Tween 60 sold 1.00 by the company ICI) Stearic acid 1.40 Triethanolamine 0.70 Carbomer 0.40 Silicone oil 12.00 Perhydrosqualene 12.00 Antioxidant 0.05 Perfume 0.5 Preservative 0.30 Water qs 100%
  • Composition 4 Gel for the treatment of lichens Sendide 5.00 Hydroxypropylcellulose (Klucel H) 1.00 Antioxidant 0.05 Isopropanol 40.00 Preservative 0.30 Water qs 100%
  • Composition 5 Cream (oil-in-water emulsion) for anal pruritus Spantide II 5.00 Cetyldimethicone copolyol 2.50 NaCl 0.60 NaOH qs pH 5 Cyclomethicone 18.00 Polypropylene glycol myristyl ether 6.00 containing 3 mol of propylene glycol Glycerol 3.00 Preservative 0.20 Water qs 100%
  • Composition 6 Cream (oil-in-water emulsion) for the treatment of severe pruritus
  • composition differs from Composition 3 by the presence of 0.05% of lidocaine instead of 1% of lactic/acetic acids.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

The invention relates to the use of a substance P antagonist for the preparation of a pharmaceutical composition, in particular for topical application, for treating lichens, prurigo, pruriginous toxicoderma and severe pruritus of neurogenic origin.

Description

  • The present invention relates to the use of a substance P antagonist for the preparation of a pharmaceutical composition for treating certain skin disorders of neurogenic origin. [0001]
  • More especially, this composition permits the treatment, topically, orally or by injection, of lichens, in particular lichen planus and pigmentary lichens; prurigo, and especially actinic prurigo, Besnier's or Hebra's prurigo or strophulus or Hyde's disease; pruriginous toxicoderma and severe pruritus of neurogenic origin, especially those of patients who have undergone haemodialysis and AIDS patients, and cholestatic or biliary pruritus. Pruriginous toxicoderma is, in particular, the outcome of the intake of a medicinal product; these disorders are very different from urticaria, and do not involve any contact reaction. [0002]
  • Hitherto, lichen planes and pigmentary lichens were treated by means of local corticoids or of PUVA therapy. Corticoids are admittedly very effective for calming the symptoms, but unfortunately they display side-effects which are often very detrimental, such as atrophy or infections, especially fungal or bacterial infections. PUVA therapy is the local irradiation of the diseased skin with UVA after absorption of a photosensitizing substance (psoralen) This technique has the serious drawbacks of a light-induced ageing which can, more often than not, give rise to skin cancers. Furthermore, this treatment is not ambulatory, commonly obliging the patients to go to a specialized centre for the entire treatment period, which is very restrictive and limits the exercising of their occupation. [0003]
  • Prurigo is also treated with local corticoids, PUVA therapy or thalidomide. Local corticoids and PUVA therapy have the above drawbacks. Thalidomide has the major drawback of being teratogenic, thereby prohibiting its use in pregnant women. Furthermore, the closely regulated prescription of this drug (limited to hospital doctors) limits its use. [0004]
  • Pruriginous toxicoderma is currently treated by means of local corticoids and/or antihistamines: its treatment hence has the same drawbacks as those mentioned above. [0005]
  • Severe pruritus is also treated with local corticoids, with the same drawbacks as those mentioned above. [0006]
  • The subject of the present invention is, in fact, the use in a pharmaceutically or dermatologically acceptable medium of one or more substance P antagonists enabling certain skin disorders to be treated effectively while remedying the. disorders mentioned above. [0007]
  • Substance P is a polypeptide chemical component produced and released by a nerve ending. It belongs to the tachykinin family. Substance P participates, in particular, in the transmission of pain and in central nervous system disorders such as anxiety and schizophrenia, in respiratory and inflammatory disorders, in gastrointestinal disorders, in rheumatic disorders and in certain skin disorders such as eczema, psoriasis, urticaria and contact dermatitis. [0008]
  • It is known to use substance P antagonists to treat these disorders. To this end, reference may be made to the documents U.S. Pat. No. 4,472,305, U.S. Pat. No. 4,839,465, EP-A-101,929, EP-A-333,174, EP-A-336,230, EP-A-394,989, EP-A-443,132, EP-A-498,069, EP-A-515,681, EP-A-517,589, WO-A-92/22569, GB-A-2,216,529, EP-A-360,390, EP-A-429,366, EP-A-430,771, EP-A-499,313, EP-A-514,273, EP-A-514,274, EP-A-514,275, EP-A-514,276, EP-A-520,555, EP-A-528,495, EP-A-532,456, EP-A-545,478, EP-A-558,156, WO-A-90/05525, WO-A-90/05729, WO-A-91/18878, WO-A-91/18899, WO-A-92/12151, WO-A-92/15585, WO-A-92/17449, WO-A-92/20676, WO-A-93/00330, WO-A-93/00331, WO-A-93/01159, WO-A-93/01169, WO-A-93/01170, WO-A-93/06099, WO-A-93/09116, EP-A-522,808, WO-A-93/01165, WO-A-93/10073 and WO-A-94/08997. [0009]
  • However, nobody had envisaged hitherto treating lichens, prurigo, pruriginous toxicoderma and severe pruritus of neurogenic origin by means of substance P antagonists. [0010]
  • Some of the documents cited above, as well as the documents JP-05-339,240 and JP-06-199,892, describe a large number of disorders which may be treated with compositions containing substance P antagonists, and, among others, some of the skin disorders also known as dermatoses. The invention relates to the symptomatic treatment (itching, irritation) of a dermatosis and not to the treatment of the disorder in itself. Thus, the invention relates to the use of a substance P-antagonist for treating the discomfort associated with certain dermatoses, and especially with eczema and with atopic dermatitis, and not to the treatment of the other signs of these dermatoses (vesicles, erythema, and the like). [0011]
  • Moreover, the skin disorders mentioned in these documents are allergies and not disorders of neurogenic origin. Now, the invention does not relate to the treatment of allergies. In effect, allergy is an immunological process which takes place only when an allergen is present and which affects only certain sensitized subjects, whereas disorders of neurogenic origin may affect any individual. [0012]
  • Consequently, the documents mentioned above neither describe nor suggest in any way the use of substance P antagonists for treating symptoms of neurogenic origin. [0013]
  • Hence the subject of the present invention is the use of at least one substance P antagonist for the preparation of a pharmaceutical or dermatological composition for treating lichens, prurigo, pruriginous toxicoderma and severe pruritus of neurogenic origin. [0014]
  • The composition of the invention contains a pharmaceutically or dermatologically acceptable medium, that is to say a medium compatible with the tissues, mucosae, skin, nails and hair. Thus, the composition containing one or more substance P antagonists may be injected, swallowed or applied to the skin, in particular of the face, neck, hair, nails, major folds or any other area of the skin of the body, and the mucosae (buccal, jugal, gingival, genital, anal). [0015]
  • For a substance to be recognized as a substance P antagonist, it must satisfy the following characteristic: [0016]
  • have a pharmacological activity antagonistic to substance P, that is to say induce a coherent pharmacological response in at least one of the following two tests: [0017]
  • the antagonist substance must decrease the extravasation of plasma through the vascular wall induced by capsaicin or by an antidromic nervous stimulation, or alternatively [0018]
  • the antagonist substance must cause an inhibition of the smooth muscle contraction induced by the administration of substance P. [0019]
  • The substance P antagonist can, in addition, have a selective affinity for the tachykinin NK1 receptors. [0020]
  • The substance P antagonist of the invention may be functional or receptor-directed, that is to say may inhibit the synthesis and/or release of substance P, or prevent its binding and/or modulate its action. [0021]
  • The substance P antagonist of the invention can be, in particular, a peptide or a non-peptide derivative, and more specifically a compound containing a nitrogen, sulphur or oxygen heterocycle, or a compound comprising a nitrogen atom linked directly or indirectly to a benzene ring. [0022]
  • It is possible to use in the invention, for example, as a substance P antagonist peptide, sendide and spantide II. [0023]
  • Sendide corresponds to the formula:[0024]
  • Tyr D-Phe Phe D-His Leu Met NH2
  • in which: [0025]
  • Tyr represents tyrosine, [0026]
  • D-Phe represents D-phenylalanine, [0027]
  • Phe represents phenylalanine, [0028]
  • D-His represents D-histidine, [0029]
  • Leu represents leucine, [0030]
  • Met represents methionine. [0031]
  • Spantide II corresponds to the formula:[0032]
  • D-NicLys Pro 3-Pal Pro D-Cl2Phe Asn D-Trp Phe D-Trp Leu Nle NH2
  • in which: [0033]
  • D-NicLys represents D-lysine nicotinate, [0034]
  • Pro represents proline, [0035]
  • 3-Pal represents 3-pyridylalanine, [0036]
  • D-Cl[0037] 2Phe represents D-dichlorophenylalanine,
  • Asn represents asparagine, [0038]
  • D-Trp represents D-tryptophan, [0039]
  • Phe represents phenylalanine, [0040]
  • Leu represents leucine, [0041]
  • Nle represents norleucine. [0042]
  • It is also possible to use in the invention, as a substance P antagonist peptide, the-peptides described in the documents U.S. Pat. No. 4,472,305, U.S. Pat. No. 4,839,465, EP-A-101,929, EP-A-333,174, EP-A-336,230, EP-A-394,989, EP-A-443,132, EP-A-498,069, EP-A-515,681, EP-A-517,589, WO-A-92/22569 and GB-A-2,216,529. [0043]
  • The non-peptide substance P antagonists which can be used in the invention are, in particular, compounds comprising a hetero atom linked directly or indirectly to a benzene ring or contained in a heterocycle. In particular, this hetero atom is an oxygen, nitrogen or sulphur atom. [0044]
  • As a heterocyclic compound containing a nitrogen atom, those described in the following documents may be used in the invention: EP-A-360,390, EP-A-429,366, EP-A-430,771, EP-A-499,313, EP-A-514,273, EP-A-514,274, EP-A-514,275, EP-A-514,276, EP-A-520,555, EP-A-528,495, EP-A-532,456, EP-A-545,478, EP-A-558,156, WO-A-90/05525, WO-A-90/05729, WO-A-91/18878, WO-A-91/18899, WO-A-92/12151, WO-A-92/15585, WO-A-92/17449, WO-A-92/20676, WO-A-93/00330, WO-A-93/00331, WO-A-93/01159, WO-A-93/01169, WO-A-93/01170, WO-A-93/06099, WO-A-93/09116 and WO-A-94/08997. [0045]
  • In particular, the compound comprising at least one nitrogen heterocycle is a 2-tricyclyl-2-aminoethane derivative, a spirolactam derivative, a quinuclidine derivative, an azacyclic derivative, an aminopyrrolidine derivative, a piperidine derivative, an aminoazaheterocycle or an isoindole derivative. [0046]
  • The compounds containing a sulphur or oxygen atom which can be used in the invention are, in particular, heterocyclic oxygen or sulphur compounds such as furan derivatives, benzofuran derivatives, thiophene derivatives and benzothiophene derivatives, optionally containing nitrogenous substituents, such as the heterocyclic compounds described in the documents U.S. Pat. No. 4,931,459, U.S. Pat. No. 4,910,317 and EP-A-299,457, and more especially alkoxy- and/or aryloxytetrazolylbenzofurancarboxamides or alkoxy-and/or aryloxytetrazolylbenzothiophenecarboxamides, [0047]
  • As compounds containing-a nitrogen atom linked directly or indirectly to a benzene ring, those described in the following documents may be mentioned: EP-A-522,808, WO-A-93/10073 and WO-A-93/01165. In particular, ethylenediamine derivatives such as N,N′-bis[bis(3,5-dimethylbenzyl)]ethylenediamine or N,N′-bis[bis(3,5-dimethoxybenzyl)]ethylenediamine may be mentioned. These compounds are described as reaction intermediates in the document WO-A-93/11338 filed in the name of the Applicant. [0048]
  • The substance P antagonists may be synthesized or extracted from natural products (plant or animal). [0049]
  • In the compositions of the invention, the substance P antagonist can preferably be used in an amount ranging from 0.000001 to 5% by weight relative to the total weight of the composition, and especially in an amount ranging from 0.0001 to 0.1% by weight relative to the total weight of the composition. [0050]
  • The compositions of the invention may be presented in all pharmaceutical dosage forms normally used, depending on whether the composition has to be swallowed, injected or applied to the skin or mucosae. [0051]
  • For topical application, the composition may take the form, in particular, of aqueous or oily solutions or of dispersions of the lotion or serum type, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersing a fatty phase in an aqueous phase (O/W) or vice versa (W/O), or of suspensions or emulsions of soft consistency of the cream or aqueous gel type or which are anhydrous, of microemulsions or alternatively of microcapsules or microparticles, or of vesicular dispersions of the ionic and/or nonionic type. These compositions are prepared according to the standard methods. [0052]
  • It may also be used for the scalp in the form of aqueous, alcoholic or aqueous-alcoholic solutions, or in the form of creams, gels, emulsions or foams, or alternatively in the form of aerosol compositions also containing a propellent agent under pressure. [0053]
  • For injection, the composition may take the form of an aqueous or oily lotion or the form of a serum. [0054]
  • For swallowing, the composition may take the form of capsules, syrup, granules or tablets. [0055]
  • The amounts of the different constituents of the composition according to the invention are those traditionally used in the fields in question. [0056]
  • These compositions constitute, in particular, cleansing, protective, treatment or skin care creams for the face, hands, feet, major anatomical folds or body, protective or skin care body milks, or lotions, gels or foams for care of the skin or mucosae, such as cleansing or disinfecting lotions, bath compositions and compositions containing a bactericidal agent. [0057]
  • The compositions according to the invention can also consist of solid preparations constituting cleansing soaps or bars. [0058]
  • The compositions may also be packaged in the form of an aerosol composition also containing a propellent agent under pressure. [0059]
  • When the composition of the invention is an emulsion, the proportion of the fatty phase can range from 5% to 80% by weight, and preferably from 5% to 50% by weight, relative to the total weight of the composition. The oils, waxes, emulsifiers and coemulsifiers used in the composition in emulsion form are chosen from those traditionally used in the cosmetics field. The emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight, relative to the total weight of the composition. The emulsion can, in addition, contain lipid vesicles. [0060]
  • When the composition is an oily gel or solution, the amount of oil can range up to more than 90% of the total weight of the composition. [0061]
  • In a known manner, the pharmaceutical or dermatological composition of the invention can also contain adjuvants which are customary in the fields in question, such as hydrophilic or lipophilic gelling agents, preservatives, antioxidants, solvents, perfumes, fillers, sunscreen agents, odour adsorbers and colouring matter. The amounts of these different adjuvants are those traditionally used in the cosmetics field, and are, for example, from 0.01% to 10% of the total weight of the composition. These adjuvants, depending on their nature, may be introduced into the fatty phase, into the aqueous phase and/or into lipid spherules. [0062]
  • As oils which can be used in the invention, mineral oils (liquid paraffin), vegetable oils (liquid fraction of shea butter, sunflower oil), animal oils (perhydrosqualene), synthetic oils (Purcellin oil), silicone oils or waxes (cyclomethicone) and fluorinated oils (perfluoro polyethers) may be mentioned. Fatty alcohols and fatty acids (stearic acid) may be added to these oils. Waxes such as beeswax and carnauba wax or paraffin may also be used. [0063]
  • As emulsifiers which can be used in the invention, glyceryl stearate, polysorbate 60 and the PEG-6/PEG-32/glycol stearate mixture sold under the name Tefose[0064] R 63 by the company Gattefosse may be mentioned as examples.
  • As solvents which can be used in the invention, lower alcohols, in particular ethanol and isopropanol, and propylene glycol may be mentioned. [0065]
  • As hydrophilic gelling agents, carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, clays and natural gums may be mentioned, and as lipophilic gelling agents, modified clays such as bentones, metal salts of fatty acids such as aluminium stearates and hydrophobic silica may be mentioned. [0066]
  • It is, in addition, possible to introduce hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, sugars and sugar derivatives, vitamins, starch, plant extracts (Aloe vera) and hydroxy acids (citric, lactic, glycolic, tartaric). [0067]
  • It is also possible to introduce lipophilic active agents such as retinol (vitamin A) and its derivatives, retinoids such as 13-cis- or all-transretinoic acid, tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides, essential oils and salicylic acid and its derivatives (5-n-octanoylsalicylic). Salicylic, lactic, acetic, and the like, acids act, in particular, as antiseptics.[0068]
  • The compositions which follow illustrate the invention: the proportions shown are percentages by weight. [0069]
    Composition 1: Disinfectant lotion for the face or
    mucosae
    N,N′-Bis[bis(3,5-dimethoxybenzyl)]ethylene- 5.00
    diamine
    Antioxidant 0.05
    Isopropanol 40.00
    Preservative 0.30
    Water qs 100%
  • This composition may be used both for treating lichen planus or pigmentary lichens and for treating pruriginous toxicoderma. [0070]
    Composition 2: Face or body gel for the treatment of
    lichen planus
    N,N′-Bis[bis(3,5-dimethoxybenzyl)]ethylene- 0.05
    diamine
    Hydroxypropylcellulose (Klucel H sold by 1.00
    the company Hercules)
    Salicylic acid 1.00
    Antioxidant 0.05
    Isopropanol 40.00
    Preservative 0.30
    Water qs 100%
  • [0071]
    Composition 3: Cream (oil-in-water emulsion) for the
    treatment of severe pruritus
    N,N′-Bis[bis(3,5-dimethoxybenzyl)]ethylene- 0.2
    diamine
    Glyceryl stearate 2.00
    Lactic acid/acetic acid 1.00
    Polysorbate 60 (Tween 60 sold 1.00
    by the company ICI)
    Stearic acid 1.40
    Triethanolamine 0.70
    Carbomer 0.40
    Silicone oil 12.00
    Perhydrosqualene 12.00
    Antioxidant 0.05
    Perfume 0.5
    Preservative 0.30
    Water qs 100%
  • [0072]
    Composition 4: Gel for the treatment of lichens
    Sendide 5.00
    Hydroxypropylcellulose (Klucel H) 1.00
    Antioxidant 0.05
    Isopropanol 40.00
    Preservative 0.30
    Water qs 100%
  • [0073]
    Composition 5: Cream (oil-in-water emulsion) for anal
    pruritus
    Spantide II 5.00
    Cetyldimethicone copolyol 2.50
    NaCl 0.60
    NaOH qs pH 5
    Cyclomethicone 18.00
    Polypropylene glycol myristyl ether 6.00
    containing 3 mol of propylene glycol
    Glycerol 3.00
    Preservative 0.20
    Water qs 100%
  • Composition 6: Cream (oil-in-water emulsion) for the treatment of severe pruritus [0074]
  • This composition differs from Composition 3 by the presence of 0.05% of lidocaine instead of 1% of lactic/acetic acids. [0075]

Claims (10)

1. Use of at least one substance P antagonist for the preparation of a pharmaceutical or dermatological composition for treating lichens, prurigo, pruriginous toxicoderma and severe pruritus of neurogenic origin.
2. Use according to claim 1, characterized in that the substance P antagonist is chosen from peptides and compounds comprising at least one. heterocycle and nitrogen compounds comprising at least one benzene ring.
3. Use according to claim 1 or 2, characterized in that the peptide is sendide or spantide II.
4. Use according to claim 1 or 2, characterized in that the compound comprising at least one heterocycle is a heterocyclic nitrogen compound chosen from 2-tricyclyl-2-aminoethane derivatives, spirolactam derivatives, quinuclidine derivatives, azacyclic derivatives, aminopyrrolidine derivatives, piperidine derivatives, aminoazaheterocycles and isoindole derivatives.
5. Use according to claim 1 or 2, characterized in that the compound comprising at least one heterocycle is a heterocyclic oxygen or sulphur compound chosen from furan derivatives, benzofuran derivatives, thiophene derivatives and benzothiophene derivatives, and in particular tetrazolylbenzofurancarboxamides or tetrazolylbenzothiophenecarboxamides.
6. Use according to claim 1 or 2, characterized in that the nitrogen compound containing at least one benzene ring is an ethylenediamine derivative.
7. Use according to any one of the preceding claims, characterized in that the substance P antagonist is used in an amount ranging from 0.000001 to 5% by weight relative to the total weight of the composition.
8. Use according to any one of the preceding claims, characterized in that the substance P antagonist is used in an amount ranging from 0.0001 to 0.1% by weight relative to the total weight of the composition.
9. Use according to any one of the preceding claims, characterized in that the composition is an aqueous, oily or aqueous-alcoholic solution, a water-in-oil emulsion, an oil-in-water emulsion, a microemulsion, an aqueous gel, an anhydrous gel, a serum or a dispersion of vesicles, of microcapsules or of microparticles.
10. Use according to any one of the preceding claims, characterized in that the composition contains at least one active agent chosen from proteins, protein hydrolysates, amino acids, polyols, urea, sugars, sugar derivatives, vitamins, starch, plant extracts, hydroxy acids, retinoids, essential fatty acids, ceramides, essential oils and salicylic acid and its derivatives.
US08/921,524 1994-12-19 1997-09-02 Use of a substance p antagonist in a pharmaceutical composition Abandoned US20020068072A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/921,524 US20020068072A1 (en) 1994-12-19 1997-09-02 Use of a substance p antagonist in a pharmaceutical composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR94-15251 1994-12-19
FR9415251A FR2728265A1 (en) 1994-12-19 1994-12-19 USE OF A SUBSTANCE P ANTAGONIST IN A PHARMACEUTICAL COMPOSITION
US08/574,653 US5679360A (en) 1994-12-19 1995-12-19 Substance P antagonist for the treatment of lichens, prurigo, pruritus
US08/921,524 US20020068072A1 (en) 1994-12-19 1997-09-02 Use of a substance p antagonist in a pharmaceutical composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/574,653 Continuation US5679360A (en) 1994-12-19 1995-12-19 Substance P antagonist for the treatment of lichens, prurigo, pruritus

Publications (1)

Publication Number Publication Date
US20020068072A1 true US20020068072A1 (en) 2002-06-06

Family

ID=9469929

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/574,653 Expired - Fee Related US5679360A (en) 1994-12-19 1995-12-19 Substance P antagonist for the treatment of lichens, prurigo, pruritus
US08/921,524 Abandoned US20020068072A1 (en) 1994-12-19 1997-09-02 Use of a substance p antagonist in a pharmaceutical composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/574,653 Expired - Fee Related US5679360A (en) 1994-12-19 1995-12-19 Substance P antagonist for the treatment of lichens, prurigo, pruritus

Country Status (14)

Country Link
US (2) US5679360A (en)
EP (1) EP0717997B1 (en)
JP (1) JPH08208506A (en)
AR (1) AR000509A1 (en)
AT (1) ATE204177T1 (en)
BR (1) BR9505382A (en)
CA (1) CA2165520C (en)
DE (1) DE69522188T2 (en)
ES (1) ES2160680T3 (en)
FR (1) FR2728265A1 (en)
HU (1) HU218921B (en)
MX (1) MX9505181A (en)
PL (1) PL311916A1 (en)
RU (1) RU2146519C1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110230566A1 (en) * 2010-03-19 2011-09-22 Maria Isabel Tamargo Perfluorocarbon eye cream formulations
WO2012044963A3 (en) * 2010-10-01 2012-07-05 Oxygen Biotherapeutics, Inc. Perfluorocarbons for use in treating pruritus

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719474B1 (en) * 1994-05-05 1996-05-31 Oreal Use of a substance P antagonist in a cosmetic composition and composition obtained.
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2732221B1 (en) * 1995-03-28 1997-04-25 Oreal USE OF A CGRP ANTAGONIST TO TREAT CUTANEOUS REDNESS OF NEUROGENIC ORIGIN AND COMPOSITION OBTAINED
FR2738742B1 (en) * 1995-09-19 1997-11-14 Oreal USE OF AT LEAST ONE VICHY THERMAL WATER AS AN ANTAGONIST OF SUBSTANCE P
FR2742054B1 (en) * 1995-12-06 1998-01-09 Synthelabo PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTI-INFLAMMATORY AGENT AND VEGETABLE CERAMIDES
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
FR2768624B1 (en) 1997-09-25 1999-11-12 Oreal USE OF AN EXCITING AMINO ACID INHIBITOR IN A COSMETIC OR DERMATOLOGICAL COMPOSITION FOR SENSITIVE SKIN AND COMPOSITION OBTAINED
US6214318B1 (en) 1997-10-02 2001-04-10 Oms Holdings Llc Aerosol ointment compositions for topical use
DE19902530C1 (en) * 1999-01-22 2000-05-25 Goldwell Gmbh Use of a composition containing ceramides and urea for treating human hair, especially as a hair conditioner
DE19902529A1 (en) * 1999-01-22 2000-08-03 Goldwell Gmbh Aqueous hair treating agent containing long-chain quaternary ammonium compound, fatty acid and urea and useful as a conditioner giving improvements in compatibility and volume as well as good gloss
EP1295599A1 (en) * 2001-09-21 2003-03-26 Boehringer Ingelheim International GmbH Method for the treatment of prevention of atopic dermatitis
JP5204657B2 (en) 2006-10-16 2013-06-05 ライオン株式会社 NK1 receptor antagonist composition
RU2443439C2 (en) * 2010-05-05 2012-02-27 Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "УрНИИДВиИ Росмедтехнологий") Method of treating lichen acuminatus
JP6815728B2 (en) 2012-10-11 2021-01-20 ネル、セラプティックス、リミテッドＮｅｒｒｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ New use
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2016012594A1 (en) * 2014-07-24 2016-01-28 Plus Vitech,S.L Neurokinin-1 receptor antagonist composition for treatment of diseases and conditions of the respiratory tract

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3772431A (en) * 1972-09-21 1973-11-13 W Mlkvy Effervescent mouthwash tablet
US3888976A (en) * 1972-09-21 1975-06-10 William P Mlkvy Zinc and strontium ion containing effervescent mouthwash tablet
US4477439A (en) * 1981-04-13 1984-10-16 Walter J. Monacelli Treatment of irritated and excoriated areas around the stoma of ostomy patients
JPS58501675A (en) * 1981-10-09 1983-10-06 フエ−リング・ア−ベ− Substance P "Kitsu" Medicinal material consisting of anti-antibiotics
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
EP0217975B1 (en) * 1985-10-08 1991-12-04 Psori-Med Ag Salt mixture for the treatment of psoriasis and other skin diseases
US4986981A (en) * 1986-07-07 1991-01-22 Den Mat Corporation Toothpaste having low abrasion
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
SE8701372L (en) * 1987-04-02 1988-10-03 Boliden Ab PROCEDURES AND RESOURCES FOR THE CONSERVATION OF HOW
DE3929411A1 (en) * 1988-09-22 1990-03-29 Siegfried Natterer Pharmaceutical preparation and process for its preparation
CA2014201A1 (en) * 1989-04-26 1990-10-26 Albemarle Corporation Solid non-hygroscopic trialkylamine oxides
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition
EP0515681A4 (en) * 1990-02-15 1993-12-29 Fujisawa Pharmaceutical Co., Ltd. Peptide compound
WO1993001160A1 (en) * 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
EP0593615B1 (en) * 1991-07-10 1996-01-31 MERCK SHARP & DOHME LTD. Aromatic compounds, compositions containing them and their use in therapy
BR9206500A (en) * 1991-09-26 1995-10-03 Pfizer Heterocycles containing condensed tricyclic nitrogen as antagonists of the P receptor substance
JP2614408B2 (en) * 1991-11-12 1997-05-28 ファイザー・インコーポレーテッド Acyclic ethylenediamine derivatives as substance P receptor antagonists
GB9201179D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
JPH05339240A (en) * 1992-06-04 1993-12-21 Yamanouchi Pharmaceut Co Ltd Tetrahydroisoquinoline amide derivative
DE4227203C2 (en) * 1992-08-17 1994-03-24 Kao Corp Gmbh Means and methods of hair treatment
JPH06199892A (en) * 1992-09-14 1994-07-19 Takeda Chem Ind Ltd Tan-1666 related comopund
GB9222486D0 (en) * 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
US5716625A (en) * 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110230566A1 (en) * 2010-03-19 2011-09-22 Maria Isabel Tamargo Perfluorocarbon eye cream formulations
WO2012044963A3 (en) * 2010-10-01 2012-07-05 Oxygen Biotherapeutics, Inc. Perfluorocarbons for use in treating pruritus
US8513309B2 (en) 2010-10-01 2013-08-20 Oxygen Biotherapeutics, Inc. Perfluorocarbons for use in treating pruritus

Also Published As

Publication number Publication date
CA2165520C (en) 2002-12-17
DE69522188T2 (en) 2001-11-29
PL311916A1 (en) 1996-06-24
HUT74746A (en) 1997-02-28
EP0717997B1 (en) 2001-08-16
FR2728265B1 (en) 1997-02-07
RU2146519C1 (en) 2000-03-20
EP0717997A1 (en) 1996-06-26
ES2160680T3 (en) 2001-11-16
HU9503624D0 (en) 1996-02-28
FR2728265A1 (en) 1996-06-21
DE69522188D1 (en) 2001-09-20
JPH08208506A (en) 1996-08-13
ATE204177T1 (en) 2001-09-15
BR9505382A (en) 1997-10-28
CA2165520A1 (en) 1996-06-20
AR000509A1 (en) 1997-07-10
MX9505181A (en) 1997-02-28
HU218921B (en) 2000-12-28
US5679360A (en) 1997-10-21

Similar Documents

Publication Publication Date Title
US5679360A (en) Substance P antagonist for the treatment of lichens, prurigo, pruritus
US5824650A (en) Topical composition containing a substance P antagoinst
US6509014B1 (en) Therapeutic/cosmetic compositions comprising CGRP antagonists for treating skin redness/rosacea/discreet erythema
US6235291B1 (en) Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
US6267972B1 (en) Cosmetic/pharmaceutical compositions comprising β-adrenergic agonists/substance P antagonists
US5744156A (en) Use of a substance P antagonist for the treatment of skin reddening of neurogenic origin
JP3054587B2 (en) Use of ethylenediamine derivatives in cosmetic compositions and cosmetic compositions containing components with irritating side effects
US5895649A (en) Method for treating neurogenic red skin blotches with compositions containing TNF-alpha antagonists
US5935586A (en) Therapeutic/cosmetic compositions comprising CGRP antagonists for treating disease states of the skin
US6333042B1 (en) Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
US5730998A (en) Use of a substance P antagonist for the treatment of pruritus, ocular and/or palpebral pain and ocular or palpebral dysaesthesia

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION